Response to immune checkpoint antibodies: Not all responses are created equal.

Response to immune checkpoint antibodies: Not all responses are created equal.

Clin Cancer Res. 2018 Dec 03;:

Authors: Cohen JV, Flaherty KT

Abstract
Early reports from immunotherapy trials conclude durable responses. Long-term data may indicate otherwise. Better delineation of clinical courses of long-term survivors will accelerate the discovery and application of biomarkers. Two pressing issues amongst those treated with anti-PD-1/PD-L1 are understanding whether responders can have therapy abbreviated and overcoming resistance in non-responders.

PMID: 30510039 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2E2hO9t